The changed psychological experience helps to facilitate the changes that people are trying to make around food, nutrition and lifestyle
Consultings Executive Insights will explore how payers should strategize their approach to glucagon-like peptide-1 agonists (GLP-1s) as they weigh rising consumer demand and increasing pharma supply with recognition of longer-term return on investment (ROI) opportunity
CMS delays Part D GLP-1 model amid skepticism from insurers. April 21, 2026
Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes
FDA-Approved Medications Only Every medication we prescribe is FDA-approved, manufactured by the original pharmaceutical company, and backed by clinical trial data
The guide to compounded tirzepatide options covers pricing, quality indicators, and what to expect from different pharmacy sources